{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:14:27Z","timestamp":1769850867269,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>The Enhanced Passive Safety Surveillance is a requirement of the European Medicines Agency (EMA) for seasonal influenza vaccines, aiming to rapidly detect any significant change in frequency or severity of expected reactogenicity or allergic events prior to widespread use of a vaccine in any particular year. The aim of this surveillance was to assess the quadrivalent inactivated split-virion influenza vaccine (IIV4) during routine immunization in Finland, as per the national immunization program for 2019\/20. The primary objective was to investigate the suspected adverse drug reactions (ADR) occurring within 7\u2009days following vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Passive surveillance of individuals vaccinated with IIV4 was conducted within the first 4 to 6\u2009weeks of the influenza season in Finland. Potential ADRs were reported via phone or posted adverse event forms. The vaccinee reporting rate and ADR reporting rate were calculated and compared with the known or expected safety data in order to identify any change which was clinically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were collected from 939 individuals, with 56 reports received for 163 suspected ADRs. Of these, 38 individuals reported 117 suspected ADRs within 7\u2009days following vaccination, corresponding to an ADR reporting rate of 12.46% (95% CI: 10.41, 14.74%); vaccination-site pain, vaccination-site reaction, and pyrexia were the most frequently reported ADRs. The 18-to-65\u2009years of age category had an ADR reporting rate of 12.56%, the over-65\u2009years of age category had an ADR reporting rate of 16.22%, and no ADRs were reported for individuals aged 6\u2009months to 18\u2009years. No serious suspected ADRs were reported at any time post-vaccination, and the ADR rates were comparable to those reported for IIV4 in the 2018\/19 seasonal assessment. The frequency of suspected ADRs was generally aligned with those reported in the Summary of Product Characteristics (SmPC), with the exception of asthenia, somnolence, and erythema, which were slightly higher. No reporting pattern by type, frequency, or severity was identified for the suspected ADRs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>No clinically significant changes in what is known or expected for IIV4 was reported for the 2019\/20 season, which supports the overall safety profile.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-10378-8","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T15:51:38Z","timestamp":1613577098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019\/20 influenza season"],"prefix":"10.1186","volume":"21","author":[{"given":"Anne-Laure","family":"Chabanon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Wague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Moureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markku","family":"Nissila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-8086","authenticated-orcid":false,"given":"Laurence","family":"Serradell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"10378_CR1","doi-asserted-by":"crossref","unstructured":"Das SR, et al. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe. 2013;13(3):314\u201323.","DOI":"10.1016\/j.chom.2013.02.008"},{"key":"10378_CR2","unstructured":"World Health Organization. virus vaccines for use in the 2020\u20132021 northern hemisphere influenza season 2020. Available at: https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/2020-21_north\/en\/ [Last accessed: Jul 2020]."},{"key":"10378_CR3","unstructured":"EMA. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf [Last accessed: Jul 2020]."},{"issue":"1","key":"10378_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4161\/hv.34360","volume":"11","author":"C Alicino","year":"2015","unstructured":"Alicino C, et al. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother. 2015;11(1):91\u20134.","journal-title":"Hum Vaccin Immunother."},{"issue":"12","key":"10378_CR5","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.4161\/hv.34369","volume":"10","author":"HJ Clothier","year":"2014","unstructured":"Clothier HJ, et al. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726\u201330.","journal-title":"Hum Vaccin Immunother"},{"key":"10378_CR6","unstructured":"Sanofi Pasteur. Summary of Product Characteristics. Vaxigrip Tetra\u00ae 2019. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/666\/smpc [Last accessed: Jul 2020]."},{"issue":"9","key":"10378_CR7","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1080\/21645515.2019.1581538","volume":"15","author":"S Gandhi-Banga","year":"2019","unstructured":"Gandhi-Banga S, et al. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017\/18 season. Hum Vaccin Immunother. 2019;15(9):2154\u20138.","journal-title":"Hum Vaccin Immunother."},{"key":"10378_CR8","unstructured":"EMA. Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4). 2017. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf [Last accessed: Dec 2020]."},{"issue":"11","key":"10378_CR9","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1080\/21645515.2019.1608745","volume":"15","author":"G Dos Santos","year":"2019","unstructured":"Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Hum Vaccin Immunother. 2019;15(11):2624\u201336.","journal-title":"Hum Vaccin Immunother."},{"key":"10378_CR10","unstructured":"FIMEA. Influenza Vaccinations. Available at: https:\/\/www.fimea.fi\/web\/en\/for_public\/influenza [Last accessed: Jul 2020]."},{"issue":"8","key":"10378_CR11","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1093\/cid\/ciaa050","volume":"71","author":"U Baum","year":"2020","unstructured":"Baum U, et al. Effectiveness of 2 influenza vaccines in Nationwide cohorts of Finnish 2-year-old children in the seasons 2015-2016 through 2017-2018. Clin Infect Dis. 2020;71(8):e255\u201361.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-021-10378-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T15:56:45Z","timestamp":1613577405000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-10378-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10378"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-10378-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"3 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As a passive surveillance system, the EPSS requires no informed consent. No sensitive data were collected about the vaccinees, and no ethics committee submission was required in Finland for the EPSS. This surveillance was conducted in accordance with the EMA\/PRAC\/222346\/2014 interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU [].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ALC, SW, and AM are employed by Sanofi Pasteur.MN is employed by Suomen Terveystalo, and has received investigator fees from Amgen, Asarina Pharma, Eli Lilly, GSK and Teva.LS is a contractor employed by Sanofi Pasteur.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}